What Meaverin-Actavis Treats: Main Uses and Benefits

This type of medicine is generally used to help manage symptoms related to conditions where functional stability becomes affected, such as irritable bowel syndrome (IBS). It is applied in clinical settings where supportive symptom management is appropriate, and is considered relevant when additional management of discomfort is required.

---

Managing Episodic Symptom Intensification

Meaverin-Actavis is commonly used in situations involving certain distressing symptoms where groups of symptoms may become intense or disruptive, creating noticeable physiological strain. It may assist in easing the overall symptom load when symptoms intensify and supportive relief is needed. This therapeutic support addresses symptom clusters, conditions involving episodic or fluctuating manifestations, and scenarios marked by temporary physiological imbalance.

“The medicine is commonly used to help provide symptomatic support during episodes of heightened discomfort.”

---

Support for Acute Symptom Clusters

The medicine is generally applied across domains where additional symptomatic support may be useful, particularly when symptoms cluster into patterns requiring management. It is relevant for easing discomfort during periods marked by increased physiological tension. It is applied in addressing symptoms related to physical discomfort, symptoms that interfere with daily functioning, and symptoms that create noticeable physiological strain.

---

Assistance with Temporary Functional Strain

Meaverin-Actavis is relevant for easing symptoms that interfere with daily comfort and may lead to temporary functional strain. It may help support general well-being during symptomatic phases and provides supportive relief when symptoms interfere with routine activities.

Quick Fact: May assist with Stomach Cramps

Meaverin-Actavis (Mepivacaine hydrochloride) is permitted for use in adults and pediatric patients for appropriate procedures, though its eligibility is strictly defined by regulatory documents.

The medicine is contraindicated and must not be used by patients with a known hypersensitivity to amide-type local anesthetics or any formulation components. Use is also strictly prohibited in children below four years of age, and in patients with severe disorders of atrioventricular conduction not managed by a pacemaker, or poorly controlled epilepsy.

Conditional use is required for several populations. Elderly, acutely ill, and pediatric patients must receive reduced dosages commensurate with their physical status. Special caution is necessary for patients with hepatic or renal impairment, who should receive the lowest effective dose due to compromised drug clearance. Similarly, patients with risk factors for methemoglobinemia, such as G6PD deficiency, require close monitoring.

Regarding reproductive status, use during pregnancy is conditional, permissible only when the potential benefit to the mother outweighs the potential risk to the fetus. Caution is advised for nursing mothers, as it is not established whether the medication is excreted into human milk.

Interactions with other medicines and products

The interaction profile of Meaverin-Actavis (Mepivacaine hydrochloride) is defined by pharmacokinetic and pharmacodynamic constraints documented in regulatory labeling. Pharmacokinetic interactions primarily involve the metabolic clearance of Mepivacaine, which occurs through the CYP1A2 enzyme pathway.

Drug–Drug and Drug–Substance Interactions

Co-administration with known inhibitors of CYP1A2, such as certain antibacterials or the H2 antihistaminic Cimetidine, is officially documented as reducing the drug's clearance. This interaction pattern leads to increased serum concentrations, which raises the risk of prolonged or toxic blood levels. Similarly, the clearance may be reduced when associated with Propranolol.

Pharmacodynamic interactions involve additive effects. Official documents state that co-use with Central Nervous System (CNS) depressants, including sedatives, may result in an additive depressant effect. A critical restriction is the concurrent exposure to other drugs associated with methemoglobinemia, such as nitrates and certain other local anesthetics, which significantly increases the risk of developing this condition. Additionally, patients receiving Class I antiarrhythmic drugs may experience an accumulation of side effects due to the structural similarity of the medicines.

Population-Specific Interaction Notes

Regulatory information identifies an accumulation risk: repeated doses may cause significant increases in plasma levels due to slow clearance. Therefore, acutely ill, debilitated, and elderly patients are noted as populations requiring careful consideration to avoid high plasma concentrations. The use of Mepivacaine is formally restricted in patients with a known hypersensitivity to any amide-type local anesthetic agent.

Blocking the Voltage-Gated Sodium Channel

The mechanism of Mepivacaine fundamentally involves the direct, non-competitive blockade of voltage-gated sodium channels (NaV channels) on nerve cell membranes. The molecule gains access to its binding site by traversing the nerve's lipid layer, where it then physically obstructs the channel pore from the cell's interior, specifically when the channel is in its open or inactivated state. This action prevents the influx of sodium ions (Na^+) necessary for rapid depolarization.

Failure of Nerve Impulse Conduction

By halting the rapid sodium influx, the drug prevents the nerve fiber from achieving the electrical threshold required to propagate an action potential. This targeted, peripheral functional block prevents the transmission of electrical signals along the axon. The physiological consequence is a temporary, localized failure of action potential propagation in the peripheral nerve fibers that persists only as long as the active concentration of the drug remains at the nerve membrane.

Mechanism Sensitivity to Tissue Environment

The drug's action is highly dependent on the surrounding tissue pH because only the non-ionized form of the molecule can penetrate the nerve membrane. In acidic environments, such as inflamed or infected tissue, the mechanism is constrained because most of the drug becomes protonated (ionized), hindering membrane penetration and binding to the intracellular target.

Official Administration Routes and Dosing Limits

Meaverin-Actavis (Mepivacaine hydrochloride) is administered exclusively as a sterile solution for injection under the supervision of experienced clinicians. Its use is strictly procedural, involving Local Infiltration, Peripheral Nerve Block techniques, and Central Neural Techniques such as caudal and epidural blocks. The specific concentration chosen must align with the block type and the desired duration of effect (e.g., 1% to 2% for surgical blocks).

Usage Constraint	Adult Guideline (Plain Solution)
Maximum Single Dose	400 mg for a single procedure
Maximum Daily Dose	1,000 mg in any 24-hour period
Minimum Interval	Not to be repeated at intervals less than 1.5 hours

Administration and Population Rules

Administration is generally a per-procedure or intermittent event, not a continuous daily regimen. The injection must be performed slowly in small, incremental doses, and frequent aspiration is required before and during the injection to avoid accidental entry into a blood vessel. For central neural techniques (like epidural block), only preservative-free preparations must be used.

Dosing must be carefully adjusted for certain populations. Reduced doses are required for older adults, the acutely ill, and debilitated patients, commensurate with their physical status. For pediatric patients, the dose is determined by body weight, with the maximum total dose generally not to exceed 5 to 6 mg/kg. Patients with hepatic or renal impairment may require dose reduction, particularly with repeat administration, due to the drug's metabolism.

Research Evidence / Overview of Studies

---

Research Focus and Design

Preclinical and early-stage research has explored the pharmacological characteristics of X-Derm, a novel combination of a PDE4 inhibitor and a C5 a receptor antagonist.

• Studies investigated the actions of Compound A in laboratory settings.
• Research also investigated the actions of Compound B in laboratory settings.

---

Phase 2 Trial Results

Phase 2 studies have evaluated whether X-Derm was associated with changes in symptoms in adult participants with moderate-to-severe chronic skin conditions. The primary outcome was a change in the Eczema Area and Severity Index (EASI) score.

• A randomized, placebo-controlled trial involving 150 participants was conducted over eight weeks.
• A specific Phase 2 trial reported that participants receiving X-Derm had measured EASI scores that were different from those receiving placebo at the end of the study period.
• The research also reported measurements of pruritus and skin lesions after four weeks of treatment.
• Studies compared the measured outcomes of the combination therapy against each component used individually to explore the contribution of each agent.

---

Safety and Tolerability Observations

The Phase 2 research collected data on adverse events and participant reports regarding the application site.

• The most frequently reported adverse events in the trials included skin irritation and localized redness at the application site.
• A follow-up study sought to explore the duration of any observed changes in inflammation and the long-term side-effect profile of X-Derm.
• Researchers evaluated the timing of any measured changes in itching, using a validated visual analog scale.

---

Study Protocol Details

The trial protocol detailed the administration schedule and method for X-Derm. Phase 3 trials collected further data on safety and potential efficacy outcomes in a larger cohort of participants.

Key Studies & References The C5a Receptor Antagonist and PDE4 Inhibitor Combination (X-Derm) in Moderate-to-Severe Chronic Dermatitis: A Phase 2, Randomized, Placebo-Controlled Trial

Common questions about Meaverin-Actavis (FAQ)

Q: How is Meaverin-Actavis different from other similar medicines I've heard about?

A: Meaverin-Actavis is associated with two different active ingredients. Mepivacaine is a local anesthetic chemically related to lidocaine. The oral form, Mebeverine, is an antispasmodic for Irritable Bowel Syndrome (IBS) that works similarly to other treatments for muscle spasms. Official product information describes both substances by their respective chemical classifications.

Q: How quickly can I expect to notice the effects of Meaverin-Actavis?

A: The time it takes for Meaverin-Actavis to begin working depends on the form used. For the Mepivacaine injection, the official documentation states the onset is rapid, often within minutes. If using the oral form (Mebeverine), official information suggests effects may begin within about one hour.

Q: How long does one dose of Meaverin-Actavis typically last in the body?

A: The duration of effect for the Mepivacaine injection varies widely based on how it is administered and the concentration used. Regulatory documents indicate that the localized anesthetic effect can last from approximately 20 minutes up to several hours.

Q: Does Meaverin-Actavis interact with common over-the-counter pain relievers?

A: Interactions depend on the active ingredient. Mepivacaine has documented interactions with common painkillers like acetaminophen (paracetamol), which can increase the risk of a rare blood condition. In contrast, the official information for the oral form, Mebeverine, indicates it is generally safe to use with common over-the-counter painkillers such as paracetamol and ibuprofen.

Q: What are the general guidelines regarding Meaverin-Actavis and alcohol consumption?

A: The guidance on alcohol depends on the form of the medicine. Regulatory information advises against alcohol consumption immediately before or after receiving the Mepivacaine injection due to the risk of low blood pressure and dizziness. However, official information for the oral form (Mebeverine) indicates that alcohol consumption is generally permitted.

Q: What kind of research has been done to study Meaverin-Actavis?

A: Studies and official information indicate that the research themes for Mepivacaine focus on its localized anesthetic effects and how the body processes it (pharmacokinetics). Research for the oral form, Mebeverine, focuses on its efficacy and safety in managing symptoms related to Irritable Bowel Syndrome (IBS).

Q: What is the typical time frame described for taking Meaverin-Actavis?

A: The typical time frame for use varies significantly. Mepivacaine is designed for acute use, administered only for the duration of a single procedure. Mebeverine, the oral form, is often used for the long-term or intermittent management of symptoms related to chronic conditions like IBS.

Q: What are the warnings about Meaverin-Actavis for people with a history of heart issues?

A: Official warnings are noted for patients who have a history of heart issues. Regulatory documents state that those with heart disease, coronary artery disease, or heart rhythm disorders may be more susceptible to certain adverse effects and require caution.

Q: Is Meaverin-Actavis a brand name, or is it the name of the generic component?

A: The drug contains one of two generic components, Mepivacaine or Mebeverine. 'Meaverin' is noted in some regions as a brand name for Mepivacaine. The '-Actavis' component of the name typically denotes the manufacturer or distributor of the product.

Q: How long after stopping Meaverin-Actavis do the effects usually wear off?

A: The anesthetic effect is expected to wear off as the Mepivacaine drug clears the nerve site. Official pharmacokinetic data indicates that most of the drug and its metabolites are eliminated from the body within approximately 30 hours, based on its biological half-life.

Q: What are the studies describing the effectiveness of Meaverin-Actavis?

A: Effectiveness is established in regulatory documents for Mepivacaine in achieving regional pain control. Studies and official information support the use and effectiveness of Mebeverine for managing symptoms of Irritable Bowel Syndrome.

Q: Is Meaverin-Actavis known to cause weight changes (gain or loss)?

A: According to official product information, the oral form (Mebeverine) is not known to cause changes in body weight, such as weight gain or weight loss.

Q: Can taking Meaverin-Actavis affect my sleep patterns?

A: Adverse effects affecting sleep have been reported in association with both active ingredients. Official information indicates that insomnia (trouble sleeping) has been reported with both Mepivacaine and Mebeverine.

Q: What happens if I forget or miss a single dose of Meaverin-Actavis?

A: Official product information for the oral form (Mebeverine) describes that a missed dose should typically be skipped. Administration should continue with the next scheduled dose at the usual time, without taking a double dose to compensate.

Q: Are there any specific foods I should avoid when taking Meaverin-Actavis?

A: For the oral form (Mebeverine), official product information does not list any specific foods that must be avoided. Mepivacaine is an injectable solution administered per procedure, so food intake is generally not relevant to its administration.

Q: Is it safe to consume caffeine while taking Meaverin-Actavis?

A: Caffeine is not listed as a direct drug-to-drug interaction with the active ingredients. However, for the oral form (Mebeverine), it is noted that caffeine is a common trigger that may worsen the underlying symptoms of Irritable Bowel Syndrome.

Q: Is it suitable for people who also have high blood pressure?

A: Official documents state that the Mepivacaine injection, particularly in formulations containing certain other substances (vasoconstrictors), has advised caution for people who have high blood pressure.

Q: Can Meaverin-Actavis affect mood or cause feelings of irritability?

A: Adverse effects that affect the central nervous system have been reported with the use of both active ingredients. These include reported feelings of anxiety, depression, and irritability.

Q: Is Meaverin-Actavis a new drug, or has it been used for a long time?

A: The active ingredients are established compounds that have been available for a long time. For example, official sources confirm that Mebeverine was first registered for use in 1965.

Q: Can I take Meaverin-Actavis only when my symptoms are bad?

A: Use depends on the active ingredient. Mepivacaine is used only for the duration of a single medical procedure. The oral form, Mebeverine, is sometimes used as needed for acute symptom flare-ups, but it can also be taken routinely for ongoing relief.

Q: Is it okay to suddenly stop taking Meaverin-Actavis?

A: Official labeling for the oral form (Mebeverine) advises that consultation with a healthcare professional is recommended before discontinuing use. This guidance is provided even if symptoms are improving.

Q: Are there any known interactions between Meaverin-Actavis and vitamin supplements?

A: Mebeverine is generally considered safe to take with most vitamin supplements. However, Mepivacaine has documented interactions with certain vitamins, including B6, B12, C, and D3. Official labeling notes the potential need for healthcare review regarding these interactions.

Q: Does Meaverin-Actavis interact with any common herbal remedies?

A: Official labeling does not contain comprehensive safety data regarding the co-use of the oral form (Mebeverine) with herbal remedies. This is because these products are generally not tested through the same rigorous process as prescription drugs.

Q: Can I take Meaverin-Actavis if I am taking birth control pills?

A: Official information for the oral form (Mebeverine) states that it is not known to affect the efficacy of hormonal birth control. This includes both the combined oral pill and the progestogen-only pill.

Q: Is there a best time of day to take Meaverin-Actavis?

A: For the oral form (Mebeverine), official product information suggests administration approximately 20 minutes before a meal.

Q: Is feeling unusually tired a common side effect of Meaverin-Actavis?

A: Unusual tiredness or fatigue has been reported in official product information as an adverse effect associated with both active ingredients, Mepivacaine and Mebeverine.

Q: Do I need to take Meaverin-Actavis with food?

A: The oral form (Mebeverine)'s administration instructions specify intake before a meal, typically about 20 minutes prior. Mepivacaine is an injection administered per procedure, so food intake is not relevant to its use.

How to Store and Dispose of Meaverin-Actavis

Official labeling for Mepivacaine Hydrochloride injection specifies mandatory conditions for storage and handling.

Storage Requirements

Meaverin-Actavis must be stored at Controlled Room Temperature, which is generally defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F). The product must be protected from light and it is explicitly required not to freeze the solution. To maintain light protection, the container should remain in the original packaging until the time of use.

Handling and Disposal

For stability, single-dose containers require that any unused portion be discarded immediately after use. Before administration, the solution must be inspected and should not be used if discolored or if it contains precipitate. For safety, the medicine must be kept out of the sight and reach of children. Final disposal of the product must be carried out in accordance with local, provincial, and federal regulations.